Kepler Cheuvreux Suisse SA Buys Shares of 276,126 Boston Scientific Corporation $BSX

Key Points

• Kepler Cheuvreux Suisse SA bought a new position of 276,126 shares of Boston Scientific in Q3, valued at about $26.96 million, representing 1.5% of its portfolio and the firm's 21st largest holding.
• CEO Michael F. Mahoney sold 160,901 shares on Feb. 2 at an average price of $93.49 for roughly $15.04 million, a 10.23% reduction in his position.
• Multiple law firms have issued class‑action notices and traders bought an unusual ~23,040 put contracts (≈27% above typical volume), signaling heightened legal scrutiny and bearish positioning as BSX was reported down about 2.8%.

Kepler Cheuvreux Suisse SA bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 276,126 shares of the medical equipment provider's stock, valued at approximately $26,955,000. Boston Scientific accounts for 1.5% of Kepler Cheuvreux Suisse SA's investment portfolio, making the stock its 21st largest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at $26,000. Steph & Co. acquired a new stake in Boston Scientific during the 3rd quarter worth $25,000. Murphy & Mullick Capital Management Corp lifted its holdings in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 170 shares in the last quarter. Financial Consulate Inc. acquired a new position in Boston Scientific in the third quarter valued at about $25,000. Finally, United Community Bank grew its stake in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 147 shares during the period. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

BSX has been the topic of a number of research analyst reports. BTIG Research reaffirmed a "buy" rating on shares of Boston Scientific in a research report on Wednesday, February 4th. Morgan Stanley decreased their price objective on Boston Scientific from $130.00 to $118.00 and set an "overweight" rating for the company in a research report on Thursday, February 5th. Stifel Nicolaus lowered their target price on Boston Scientific from $125.00 to $110.00 and set a "buy" rating for the company in a research note on Wednesday, February 4th. Sanford C. Bernstein restated an "outperform" rating and set a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Finally, Canaccord Genuity Group cut their price target on shares of Boston Scientific from $112.00 to $109.00 and set a "buy" rating on the stock in a research note on Tuesday, February 17th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $108.36.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Investor alert from TMCNet flags a securities‑fraud lawsuit and solicits investors to consider leading the class action. BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit
• Negative Sentiment: Bragar Eagel & Squire announces an investigation on behalf of long‑term BSX shareholders and invites contact regarding losses. BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire
• Negative Sentiment: Rosen Law Firm public notice: a class action was filed covering the same class period and warns investors to secure counsel before the May 4 deadline. ROSEN Encourages Boston Scientific Investors to Secure Counsel
• Negative Sentiment: Robbins Geller Rudman & Dowd notifies investors of opportunity to seek lead‑plaintiff status in the filed class action (same class period). INVESTOR ALERT: RGRD Law
• Negative Sentiment: Faruqi & Faruqi issues a reminder about the May 4, 2026 deadline for investors to seek lead‑plaintiff appointment in the securities class action. Faruqi & Faruqi Reminder
• Negative Sentiment: Law Offices of Frank R. Cruz encourages BSX shareholders to inquire about a securities fraud class action — another solicitor notice piling on legal attention. Frank R. Cruz Notice
• Negative Sentiment: The Gross Law Firm posts a shareholder notice about a class action and the May 4 deadline to join as a plaintiff. Gross Law Firm Notice
• Negative Sentiment: Portnoy Law Firm announces a class action for investors who bought BSX during the stated class period and highlights the lead‑plaintiff deadline. Portnoy Law Firm Announcement
• Negative Sentiment: Bernstein Liebhard issues a shareholder alert confirming a securities‑fraud class action has been filed against Boston Scientific. Bernstein Liebhard Alert
• Negative Sentiment: Levi & Korsinsky notifies shareholders about the class action and encourages contact before the May 4 deadline. Levi & Korsinsky Notice
• Negative Sentiment: Robbins LLP issues a class action notice covering the same class period and urging investor contact. Robbins LLP Notice
• Negative Sentiment: Unusual options activity: traders bought ~23,040 put contracts on Monday (≈27% above typical put volume), signaling increased bearish positioning or hedging demand. Options Activity Report

Boston Scientific Stock Down 2.8%

NYSE:BSX opened at $69.90 on Wednesday. Boston Scientific Corporation has a twelve month low of $69.52 and a twelve month high of $109.50. The firm has a market capitalization of $103.72 billion, a price-to-earnings ratio of 36.03, a price-to-earnings-growth ratio of 1.01 and a beta of 0.69. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The stock's 50 day moving average price is $84.03 and its two-hundred day moving average price is $93.98.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analysts' expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm's revenue was up 15.9% on a year-over-year basis. During the same period last year, the business earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.